Eko Devices gets FDA nod for its DUO digital stethoscope and ECG combo

The FDA clears Eko Devices' DUO remote heart device monitor.

The FDA has cleared Eko Devices’ portable cardiac device that combines a digital stethoscope with electrocardiogram (ECG), allowing cardiologists and patients to better monitor heart disease, the company said.

Dubbed the DUO, the compact, handheld device gives physicians and clinicians a screening tool for heart disease patients as part of their home-health kit. The device, which is only available by prescription, is matched with the company’s secure, HIPAA-compliant app that allows for remote monitoring and diagnosis.

Heart disease is the leading cause of death in the U.S., according to the CDC. About $26 billion is spent each year on hospitalization related to heart failure, according to the American Heart Association. Studies have shown that 25% of heart failure patients are readmitted to the hospital within 30 days and 50% are readmitted within six months, the company said.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"Cardiology programs are looking for ways to deliver hospital-quality healthcare at home," Ami Bhatt, M.D., director of Outpatient Cardiology and the Adult Congenital Heart Disease Program at Massachusetts General Hospital, said in a statement. "The ability to capture digital heart sounds and an ECG expands our portfolio of mechanisms to remotely monitor the heart, and brings diagnosis and opportunities for early intervention even further upstream.”

The company also said it is currently working on machine-learning algorithms that can be combined with DUO to alert patients and their care teams of a decline in cardiac function.

Eko’s digital stethoscope enhancement grew out of Skydeck, the University of California-Berkley’s startup accelerator. In 2015, the company received $2 million in funding to boost the development process of the device.


Suggested Articles

Belgian devicemaker Miracor Medical received a breakthrough designation from the FDA for its treatment designed to limit the damage of a heart attack.

Following an FBI raid and the replacement of its leadership, it’s come to light that the data behind uBiome’s microbiome test may contain flaws.

The National Institutes of Health has tapped the genomics firm Color to help participants understand and act on their results.